tiprankstipranks
Cochlear Limited (CH:OC5)
:OC5
Switzerland Market
OC5
Cochlear
RESEARCH TOOLSreports

Cochlear (OC5) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

OC5 Analyst Ratings

Hold
12Ratings
Hold
3 Buy
8 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Cochlear
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OC5 Stock 12 Month Forecast

Average Price Target

CHF75.39
Based on 12 Wall Street analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is CHF75.39 with a high forecast of CHF121.91 and a low forecast of CHF53.67. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF121.91Average Price TargetCHF75.39Lowest Price TargetCHF53.67
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CH:OC5
David Low
UBS
UBS
―
Hold
―
Downgraded
05/01/26
UBS downgrades Cochlear (CHEOF) to a Hold
Canaccord Genuity Analyst forecast on CH:OC5
Shane Storey
Canaccord Genuity
Canaccord Genuity
CHF166.66→CHF67.79
Buy
―
Reiterated
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)
J.P. Morgan Analyst forecast on CH:OC5
Chris Cooper
J.P. Morgan
J.P. Morgan
CHF62.71
Hold
―
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Cochlear (Other OTC: CHEOF) and Boston Scientific (NYSE: BSX)
Ord Minnett Analyst forecast on CH:OC5
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
CHF126.55→CHF87
Hold
―
Reiterated
04/23/26
Ord Minnett Sticks to Their Hold Rating for Cochlear (CHEOF)
Jefferies Analyst forecast on CH:OC5
David Stanton
Jefferies
Jefferies
CHF161.01→CHF77.4
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), Cochlear (Other OTC: CHEOF) and Definium Therapeutics (NASDAQ: DFTX)
Morgan Stanley Analyst forecast on CH:OC5
David Bailey
Morgan Stanley
Morgan Stanley
CHF109.6→CHF67.23
Hold
―
Upgraded
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)
Morgans Analyst forecast on CH:OC5
Derek Jellinek
Morgans
Morgans
CHF121.42→CHF60.54
Hold
―
Reiterated
04/23/26
Cochlear (CHEOF) Gets a Hold from Morgans
Macquarie Analyst forecast on CH:OC5
Unknown Analyst
Macquarie
Not Ranked
Macquarie
CHF135.02→CHF64.97
Hold
―
Reiterated
04/22/26
Macquarie Sticks to Their Hold Rating for Cochlear (CHEOF)
Jarden Analyst forecast on CH:OC5
Steven Wheen
Jarden
Jarden
CHF126.55→CHF95.47
Hold
―
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)
Citi Analyst forecast on CH:OC5
Laura Sutcliffe
Citi
Citi
CHF118.64→CHF53.67
Sell
―
Downgraded
04/22/26
Cochlear Downgraded to Sell on Structurally Weaker Growth, Demand Risks, and Margin Pressure
RBC Capital Analyst forecast on CH:OC5
Craig Wong-Pan
RBC Capital
RBC Capital
CHF167.79→CHF70.62
Buy
―
Reiterated
04/22/26
RBC Capital Keeps Their Buy Rating on Cochlear (CHEOF)
Goldman Sachs Analyst forecast on CH:OC5
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
CHF138.35→CHF121.91
Hold
―
Reiterated
03/13/26
Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CH:OC5
David Low
UBS
UBS
―
Hold
―
Downgraded
05/01/26
UBS downgrades Cochlear (CHEOF) to a Hold
Canaccord Genuity Analyst forecast on CH:OC5
Shane Storey
Canaccord Genuity
Canaccord Genuity
CHF166.66→CHF67.79
Buy
―
Reiterated
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)
J.P. Morgan Analyst forecast on CH:OC5
Chris Cooper
J.P. Morgan
J.P. Morgan
CHF62.71
Hold
―
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Cochlear (Other OTC: CHEOF) and Boston Scientific (NYSE: BSX)
Ord Minnett Analyst forecast on CH:OC5
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
CHF126.55→CHF87
Hold
―
Reiterated
04/23/26
Ord Minnett Sticks to Their Hold Rating for Cochlear (CHEOF)
Jefferies Analyst forecast on CH:OC5
David Stanton
Jefferies
Jefferies
CHF161.01→CHF77.4
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (NASDAQ: MEDP), Cochlear (Other OTC: CHEOF) and Definium Therapeutics (NASDAQ: DFTX)
Morgan Stanley Analyst forecast on CH:OC5
David Bailey
Morgan Stanley
Morgan Stanley
CHF109.6→CHF67.23
Hold
―
Upgraded
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)
Morgans Analyst forecast on CH:OC5
Derek Jellinek
Morgans
Morgans
CHF121.42→CHF60.54
Hold
―
Reiterated
04/23/26
Cochlear (CHEOF) Gets a Hold from Morgans
Macquarie Analyst forecast on CH:OC5
Unknown Analyst
Macquarie
Not Ranked
Macquarie
CHF135.02→CHF64.97
Hold
―
Reiterated
04/22/26
Macquarie Sticks to Their Hold Rating for Cochlear (CHEOF)
Jarden Analyst forecast on CH:OC5
Steven Wheen
Jarden
Jarden
CHF126.55→CHF95.47
Hold
―
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)
Citi Analyst forecast on CH:OC5
Laura Sutcliffe
Citi
Citi
CHF118.64→CHF53.67
Sell
―
Downgraded
04/22/26
Cochlear Downgraded to Sell on Structurally Weaker Growth, Demand Risks, and Margin Pressure
RBC Capital Analyst forecast on CH:OC5
Craig Wong-Pan
RBC Capital
RBC Capital
CHF167.79→CHF70.62
Buy
―
Reiterated
04/22/26
RBC Capital Keeps Their Buy Rating on Cochlear (CHEOF)
Goldman Sachs Analyst forecast on CH:OC5
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
CHF138.35→CHF121.91
Hold
―
Reiterated
03/13/26
Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cochlear

3 Months
Shane StoreyCanaccord Genuity
Success Rate
4/9 ratings generated profit
44%
Average Return
-5.14%
Copying Shane Storey's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -5.14% per trade.
1 Year
David StantonJefferies
Success Rate
3/9 ratings generated profit
33%
Average Return
-37.07%
Copying David Stanton's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -37.07% per trade.
2 Years
David StantonJefferies
Success Rate
2/9 ratings generated profit
22%
Average Return
-46.09%
Copying David Stanton's trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -46.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OC5 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
3
5
5
2
Buy
6
6
8
3
3
Hold
10
10
14
9
8
Sell
2
3
3
2
1
Strong Sell
0
0
0
0
0
total
18
22
30
19
14
In the current month, OC5 has received 5 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. OC5 average Analyst price target in the past 3 months is 75.39.
Each month's total comprises the sum of three months' worth of ratings.

OC5 Financial Forecast

OC5 Earnings Forecast

Next quarter’s earnings estimate for OC5 is CHF0.97 with a range of CHF0.88 to CHF1.07. The previous quarter’s EPS was CHF1.67. OC5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.
Next quarter’s earnings estimate for OC5 is CHF0.97 with a range of CHF0.88 to CHF1.07. The previous quarter’s EPS was CHF1.67. OC5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Sales Forecast

Next quarter’s sales forecast for OC5 is CHF660.64M with a range of CHF623.57M to CHF711.97M. The previous quarter’s sales results were CHF659.27M. OC5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.
Next quarter’s sales forecast for OC5 is CHF660.64M with a range of CHF623.57M to CHF711.97M. The previous quarter’s sales results were CHF659.27M. OC5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Stock Forecast FAQ

What is CH:OC5’s average 12-month price target, according to analysts?
Based on analyst ratings, Cochlear Limited’s 12-month average price target is 75.39.
    What is CH:OC5’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:OC5, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Cochlear Limited a Buy, Sell or Hold?
        Cochlear Limited has a consensus rating of Hold, which is based on 3 buy ratings, 8 hold ratings and 1 sell ratings.
          What is Cochlear Limited’s share price target?
          The average share price target for Cochlear Limited is 75.39. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF121.91 ,and the lowest forecast is CHF53.67. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Cochlear Limited?
            Cochlear Limited’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of Cochlear Limited?
              To buy shares of CH:OC5, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.